PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
-26.17%
Negative ROE indicates either losses or negative equity – a major Benjamin Graham warning. Confirm if leverage or poor profitability is the cause.
13636.67%
ROA above 20% – Exceptional asset efficiency. Peter Lynch would check if this is sustained by a durable growth strategy.
13.77%
ROCE 10-15% – Moderate. Peter Lynch would see if higher reinvestment can lift returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.